Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Receivables (2020 - 2025)

Historic Change in Receivables for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $12.9 million.

  • GeneDx Holdings' Change in Receivables rose 351.19% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 25434.82%. This contributed to the annual value of $5.4 million for FY2024, which is 15282.08% up from last year.
  • As of Q3 2025, GeneDx Holdings' Change in Receivables stood at $12.9 million, which was up 351.19% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Change in Receivables registered a high of $12.9 million during Q3 2025, and its lowest value of -$13.5 million during Q2 2022.
  • Its 5-year average for Change in Receivables is $362894.7, with a median of -$429000.0 in 2024.
  • Over the last 5 years, GeneDx Holdings' Change in Receivables had its largest YoY gain of 235942.03% in 2024, and its largest YoY loss of 43259.42% in 2024.
  • Quarter analysis of 5 years shows GeneDx Holdings' Change in Receivables stood at $5.3 million in 2021, then plummeted by 100.69% to -$36000.0 in 2022, then skyrocketed by 1386.11% to $463000.0 in 2023, then plummeted by 192.66% to -$429000.0 in 2024, then surged by 3109.32% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, $1.3 million for Q2 2025, and $8.6 million during Q1 2025.